PathAI remains an independent company, focused on developing innovative AI and digital pathology solutions SECAUCUS, N.J. and BOSTON, June 11, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information...

PathAI: Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs  SECAUCUS, N.J. and BOSTON –...

To help build out its own portfolio of artificial-intelligence-driven pathology tests, Quest Diagnostics has enlisted the help of Paige to develop a suite of products aimed at individual clinical oncologists as well as larger biopharma...